<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32655545</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.</ArticleTitle>
        <Pagination>
          <StartPage>991</StartPage>
          <MedlinePgn>991</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">991</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.00991</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic cerebellar degeneration (PCD) is a rare immune-mediated disease that develops mostly in the setting of neoplasia and offers a unique prospect to explore the interplay between tumor immunity and autoimmunity. In PCD, the deleterious adaptive immune response targets self-antigens aberrantly expressed by tumor cells, mostly gynecological cancers, and physiologically expressed by the Purkinje neurons of the cerebellum. Highly specific anti-neuronal antibodies in the serum and cerebrospinal fluid represent key diagnostic biomarkers of PCD. Some anti-neuronal antibodies such as anti-Yo autoantibodies (recognizing the CDR2/CDR2L proteins) are only associated with PCD. Other anti-neuronal antibodies, such as anti-Hu, anti-Ri, and anti-Ma2, are detected in patients with PCD or other types of paraneoplastic neurological manifestations. Importantly, these autoantibodies cannot transfer disease and evidence for a pathogenic role of autoreactive T cells is accumulating. However, the precise mechanisms responsible for disruption of self-tolerance to neuronal self-antigens in the cancer setting and the pathways involved in pathogenesis within the cerebellum remain to be fully deciphered. Although the occurrence of PCD is rare, the risk for such severe complication may increase with wider use of cancer immunotherapy, notably immune checkpoint blockade. Here, we review recent literature pertaining to the pathophysiology of PCD and propose an immune scheme underlying this disabling disease. Additionally, based on observations from patients' samples and on the pre-clinical model we recently developed, we discuss potential therapeutic strategies that could blunt this cerebellum-specific autoimmune disease.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Yshii, Bost and Liblau.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yshii</LastName>
            <ForeName>Lidia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U1043, CNRS UMR 5282, Université Toulouse III, Center for Pathophysiology Toulouse Purpan, Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bost</LastName>
            <ForeName>Chloé</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U1043, CNRS UMR 5282, Université Toulouse III, Center for Pathophysiology Toulouse Purpan, Toulouse, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Purpan University Hospital Toulouse, Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liblau</LastName>
            <ForeName>Roland</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM U1043, CNRS UMR 5282, Université Toulouse III, Center for Pathophysiology Toulouse Purpan, Toulouse, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Immunology, Purpan University Hospital Toulouse, Toulouse, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C095184">CDR2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000599484">CDR2L antigen, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">T cell</Keyword>
        <Keyword MajorTopicYN="Y">animal model</Keyword>
        <Keyword MajorTopicYN="Y">anti-neuronal antibodies</Keyword>
        <Keyword MajorTopicYN="Y">autoimmunity</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic cerebellar degeneration</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32655545</ArticleId>
        <ArticleId IdType="pmc">PMC7326021</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2020.00991</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Waisman A, Liblau RS, Becher B. Innate and adaptive immune responses in the CNS. Lancet Neurol. (2015) 14:945–55. 10.1016/S1474-4422(15)00141-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00141-6</ArticleId>
            <ArticleId IdType="pubmed">26293566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, et al. . T cells of Parkinson's disease patients recognize α-synuclein peptides. Nature. (2017) 546:656–61. 10.1038/nature22815</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22815</ArticleId>
            <ArticleId IdType="pmc">PMC5626019</ArticleId>
            <ArticleId IdType="pubmed">28636593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, et al. . T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. (2018) 562:63–8. 10.1038/s41586-018-0540-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0540-1</ArticleId>
            <ArticleId IdType="pubmed">30232458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. . Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. Nature. (2020) 577:399–404. 10.1038/s41586-019-1895-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1895-7</ArticleId>
            <ArticleId IdType="pmc">PMC7445078</ArticleId>
            <ArticleId IdType="pubmed">31915375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Illa I, Agusti M, Ribalta T, Cruz-Sanchez F, Juarez C. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci. (1991) 106:82–7. 10.1016/0022-510X(91)90198-G</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(91)90198-G</ArticleId>
            <ArticleId IdType="pubmed">1779243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furneaux HM, Rosenblum MK, Dalmau J, Wong E, Woodruff P, Graus F, et al. . Selective expression of Purkinje cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med. (1990) 322:1844–51. 10.1056/NEJM199006283222604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199006283222604</ArticleId>
            <ArticleId IdType="pubmed">2348838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. (2008) 7:327–40. 10.1016/S1474-4422(08)70060-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy. Sci Transl Med. (2016) 8:328rv4. 10.1126/scitranslmed.aad7118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aad7118</ArticleId>
            <ArticleId IdType="pmc">PMC4859220</ArticleId>
            <ArticleId IdType="pubmed">26936508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med. (1998) 4:1321–4. 10.1038/3315</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/3315</ArticleId>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, et al. . Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest. (2009) 119:2042–51. 10.1172/JCI36131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI36131</ArticleId>
            <ArticleId IdType="pmc">PMC2701858</ArticleId>
            <ArticleId IdType="pubmed">19509467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillary RP, Ollila HM, Lin L, Desestret V, Rogemond V, Picard G, et al. . Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. J Neuroimmunol. (2018) 315:28–32. 10.1016/j.jneuroim.2017.12.012</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.12.012</ArticleId>
            <ArticleId IdType="pubmed">29306402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration : I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. (1992) 42:1931–7. 10.1212/WNL.42.10.1931</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.42.10.1931</ArticleId>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. (2014) 128:835–52. 10.1007/s00401-014-1351-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-014-1351-6</ArticleId>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, et al. . CDR2L antibodies : a new player in paraneoplastic cerebellar degeneration. PLoS ONE. (2013) 8:e66002. 10.1371/journal.pone.0066002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0066002</ArticleId>
            <ArticleId IdType="pmc">PMC3688866</ArticleId>
            <ArticleId IdType="pubmed">23823982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. (1998) 50:652–7. 10.1212/WNL.50.3.652</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.50.3.652</ArticleId>
            <ArticleId IdType="pubmed">9521251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. . Anti-Hu-associated paraneoplastic encephalomyelitis : analysis of 200 patients. Brain. (2001) 124:1138–48. 10.1093/brain/124.6.1138</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.6.1138</ArticleId>
            <ArticleId IdType="pubmed">11353730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Graus F, Rosenblum M, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy : a clinical study of 71 patients. Medicine (Baltimore). (1992) 71:59–72. 10.1097/00005792-199203000-00001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-199203000-00001</ArticleId>
            <ArticleId IdType="pubmed">1312211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, et al. . Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. (2001) 58:225–30. 10.1001/archneur.58.2.225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.58.2.225</ArticleId>
            <ArticleId IdType="pubmed">11176960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, et al. . Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol. (2010) 229:219–24. 10.1016/j.jneuroim.2010.07.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2010.07.019</ArticleId>
            <ArticleId IdType="pubmed">20813415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kono S, Miyajima H, Sugimoto M, Suzuki Y, Takahashi Y, Hishida A. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern Med. (2001) 40:968–71. 10.2169/internalmedicine.40.968</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.40.968</ArticleId>
            <ArticleId IdType="pubmed">11579968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci. (2010) 290:148–9. 10.1016/j.jns.2009.12.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2009.12.006</ArticleId>
            <ArticleId IdType="pubmed">20056249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al. . Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. (2008) 131:2553–63. 10.1093/brain/awn183</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn183</ArticleId>
            <ArticleId IdType="pubmed">18687732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B. A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation. (2010) 7:21. 10.1186/1742-2094-7-21</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-7-21</ArticleId>
            <ArticleId IdType="pmc">PMC2848133</ArticleId>
            <ArticleId IdType="pubmed">20226058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Martínez-García P, Hernandez AL, Brase JC, Borowski K, Regula JU, et al. . Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation. (2013) 10:7. 10.1186/1742-2094-10-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-10-7</ArticleId>
            <ArticleId IdType="pmc">PMC3549891</ArticleId>
            <ArticleId IdType="pubmed">23320754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doss S, Nümann A, Ziegler A, Siebert E, Borowski K, Stöcker W, et al. . Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. J Neuroimmunol. (2014) 267:102–4. 10.1016/j.jneuroim.2013.10.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.10.010</ArticleId>
            <ArticleId IdType="pubmed">24439423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartels F, Prüss H, Finke C. Anti-ARHGAP26 autoantibodies are associated with isolated cognitive impairment. Front Neurol. (2018) 9:656. 10.3389/fneur.2018.00656</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00656</ArticleId>
            <ArticleId IdType="pmc">PMC6104436</ArticleId>
            <ArticleId IdType="pubmed">30158896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F. From dizziness to severe ataxia and dysarthria: new cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. J Neuroimmunol. (2017) 309:77–81. 10.1016/j.jneuroim.2017.05.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.05.011</ArticleId>
            <ArticleId IdType="pubmed">28601293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shan F, Long Y, Qiu W. Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature. Front Immunol. (2018) 9:2802. 10.3389/fimmu.2018.02802</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02802</ArticleId>
            <ArticleId IdType="pmc">PMC6290896</ArticleId>
            <ArticleId IdType="pubmed">30568655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. (2001) 49:146–54. 10.1002/1531-8249(20010201)49:2&lt;146::aid-ana34&gt;3.0.co</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;146::aid-ana34&gt;3.0.co</ArticleId>
            <ArticleId IdType="pubmed">11220734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoine JC, Honnorat J, Vocanson C, Koenig F, Aguera M, Belin MF, et al. . Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci. (1993) 117:215–23. 10.1016/0022-510X(93)90176-Y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(93)90176-Y</ArticleId>
            <ArticleId IdType="pubmed">8410058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. . Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. (2009) 80:412–6. 10.1136/jnnp.2007.138016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.138016</ArticleId>
            <ArticleId IdType="pmc">PMC2664637</ArticleId>
            <ArticleId IdType="pubmed">18931014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. (1996) 61:270–8. 10.1136/jnnp.61.3.270</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.61.3.270</ArticleId>
            <ArticleId IdType="pmc">PMC486550</ArticleId>
            <ArticleId IdType="pubmed">8795598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Chiriboga AS, Komorowski L, Kümpfel T, Probst C, Hinson SR, Pittock SJ, et al. . Metabotropic glutamate receptor type 1 autoimmunity : clinical features and treatment outcomes. Neurology. (2016) 86:1009–13. 10.1212/WNL.0000000000002476</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002476</ArticleId>
            <ArticleId IdType="pmc">PMC4799712</ArticleId>
            <ArticleId IdType="pubmed">26888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C, Cavillon G, et al. . Metabotropic glutamate receptor type 1 autoantibody–associated cerebellitis. Arch Neurol. (2010) 67:627–30. 10.1001/archneurol.2010.51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2010.51</ArticleId>
            <ArticleId IdType="pubmed">20457964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sillevis-Smitt P, Kinoshita M, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. . Paraneoplastic cerebellar ataxia due to autoantibodies against glutamate receptor. N Engl J Med. (2000) 342:21–7. 10.1056/NEJM200001063420104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM200001063420104</ArticleId>
            <ArticleId IdType="pubmed">10620645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iorio R, Damato V, Mirabella M, Vita MG, Hulsenboom E, Plantone D, et al. . Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. J Neuroimmunol. (2013) 263:155–8. 10.1016/j.jneuroim.2013.07.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.07.015</ArticleId>
            <ArticleId IdType="pubmed">23958353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. . Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. (1997) 120:1279–300. 10.1093/brain/120.8.1279</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/120.8.1279</ArticleId>
            <ArticleId IdType="pubmed">9278623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P / Q type calcium- channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. (2002) 59:764–6. 10.1212/WNL.59.5.764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.59.5.764</ArticleId>
            <ArticleId IdType="pubmed">12221175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bürk K, Wick M, Roth G, Decker P, Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol. (2010) 257:59–62. 10.1007/s00415-009-5262-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5262-8</ArticleId>
            <ArticleId IdType="pubmed">19629562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. . Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. (2005) 58:96–107. 10.1002/ana.20529</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20529</ArticleId>
            <ArticleId IdType="pubmed">15984030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon J, Lee S-T, Shin J-W, Byun J-I, Lim J-A, Shin Y-W, et al. . Non-stiff anti-amphiphysin syndrome: clinical manifestations and outcome after immunotherapy. J Neuroimmunol. (2014) 274:209–14. 10.1016/j.jneuroim.2014.07.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.07.011</ArticleId>
            <ArticleId IdType="pubmed">25087755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, et al. . Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. (2014) 82:1521–8. 10.1212/WNL.0000000000000372</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000372</ArticleId>
            <ArticleId IdType="pubmed">24696508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, et al. . Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. (2013) 73:120–8. 10.1002/ana.23756</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23756</ArticleId>
            <ArticleId IdType="pmc">PMC3563722</ArticleId>
            <ArticleId IdType="pubmed">23225603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. . DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. (2014) 83:1797–803. 10.1212/WNL.0000000000000991</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000991</ArticleId>
            <ArticleId IdType="pmc">PMC4240433</ArticleId>
            <ArticleId IdType="pubmed">25320100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoeck K, Carstens PO, Jarius S, Raddatz D, Stöcker W, Wildemann B, et al. . Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol NeuroInflamm. (2015) 2:e86. 10.1212/NXI.0000000000000086</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000086</ArticleId>
            <ArticleId IdType="pmc">PMC4360797</ArticleId>
            <ArticleId IdType="pubmed">25798450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker EBE, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, et al. . Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry. (2012) 83:437–40. 10.1136/jnnp-2011-301506</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-301506</ArticleId>
            <ArticleId IdType="pmc">PMC3297806</ArticleId>
            <ArticleId IdType="pubmed">22338029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balint B, Regula JU, Jarius S, Wildemann B. Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci. (2013) 327:73–4. 10.1016/j.jns.2013.01.040</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.01.040</ArticleId>
            <ArticleId IdType="pubmed">23465509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannoth S, Nambiar V, Gopinath S, Anandakuttan A, Mathai A, Rajan PK. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity—syndrome of parkinsonism and ataxia. Neurol Sci. (2018) 39:455–60. 10.1007/s10072-017-3222-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-017-3222-0</ArticleId>
            <ArticleId IdType="pubmed">29264691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. (2011) 76:795–800. 10.1212/WNL.0b013e31820e7b8d</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31820e7b8d</ArticleId>
            <ArticleId IdType="pmc">PMC3053332</ArticleId>
            <ArticleId IdType="pubmed">21357831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. . Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. (2010) 9:67–76. 10.1016/S1474-4422(09)70324-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70324-2</ArticleId>
            <ArticleId IdType="pmc">PMC2824142</ArticleId>
            <ArticleId IdType="pubmed">19962348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. . GABA B receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol. (2013) 256:94–6. 10.1016/j.jneuroim.2012.12.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2012.12.006</ArticleId>
            <ArticleId IdType="pubmed">23332614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. . Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. (2005) 165:166–71. 10.1016/j.jneuroim.2005.03.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2005.03.020</ArticleId>
            <ArticleId IdType="pmc">PMC2586939</ArticleId>
            <ArticleId IdType="pubmed">15949849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. . SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. (2009) 27:4260–7. 10.1200/JCO.2008.20.6169</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.20.6169</ArticleId>
            <ArticleId IdType="pubmed">19667272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, et al. . Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. (2008) 79:767–73. 10.1136/jnnp.2007.118588</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.118588</ArticleId>
            <ArticleId IdType="pubmed">18223018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. . Clinical analysis of anti-Ma2-associated encephalitis. Brain. (2004) 127:1831–44. 10.1093/brain/awh203</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh203</ArticleId>
            <ArticleId IdType="pubmed">15215214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. . A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. (1999) 340:1788–95. 10.1056/NEJM199906103402303</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199906103402303</ArticleId>
            <ArticleId IdType="pubmed">10362822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, et al. . Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain. (1999) 122:27–39. 10.1093/brain/122.1.27</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/122.1.27</ArticleId>
            <ArticleId IdType="pubmed">10050892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. (2003) 53:580–7. 10.1002/ana.10518</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10518</ArticleId>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budde-Steffen C, Anderson NE, Rosenblum MK, Graus F, Ford D, Synek BJL, et al. . An antineuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol. (1988) 23:528–31. 10.1002/ana.410230518</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410230518</ArticleId>
            <ArticleId IdType="pubmed">3389761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Leary CG, Battley JE, O'Reilly S. Anti-Ri antibody associated small cell lung carcinoma. Ir J Med Sci. (2016) 186:265–7. 10.1007/s11845-016-1402-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11845-016-1402-1</ArticleId>
            <ArticleId IdType="pubmed">26833486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. (2000) 47:297–305. 10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200003)47:3&lt;297::AID-ANA4&gt;3.0.CO;2-4</ArticleId>
            <ArticleId IdType="pubmed">10716248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. (2001) 50:301–11. 10.1002/ana.1127</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.1127</ArticleId>
            <ArticleId IdType="pubmed">11558786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Wade DF, Fuller GN, Rosenfeld MR, Dalmau J. Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum. Neurology. (2002) 59:1985–7. 10.1212/01.WNL.0000038352.01415.CE</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000038352.01415.CE</ArticleId>
            <ArticleId IdType="pubmed">12499499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. (2004) 62:778–82. 10.1212/01.WNL.0000113749.77217.01</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000113749.77217.01</ArticleId>
            <ArticleId IdType="pmc">PMC2574539</ArticleId>
            <ArticleId IdType="pubmed">15007130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F.
ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol. (2008) 201–2:163–5. 10.1016/j.jneuroim.2008.01.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.01.018</ArticleId>
            <ArticleId IdType="pmc">PMC2582201</ArticleId>
            <ArticleId IdType="pubmed">18639938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuliani L, Sabater L, Saiz A, Baiges J, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. (2007) 68:239–40. 10.1212/01.wnl.0000251308.79366.f9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000251308.79366.f9</ArticleId>
            <ArticleId IdType="pubmed">17224583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol. (2013) 70:506–9. 10.1001/jamaneurol.2013.1955</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2013.1955</ArticleId>
            <ArticleId IdType="pmc">PMC3723144</ArticleId>
            <ArticleId IdType="pubmed">23400636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Scharf M, Begemann N, Stöcker W, Probst C, Serysheva II, et al. . Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflammation. (2014) 11:206. 10.1186/s12974-014-0206-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-014-0206-3</ArticleId>
            <ArticleId IdType="pmc">PMC4300617</ArticleId>
            <ArticleId IdType="pubmed">25498830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berzero G, Hacohen Y, Komorowski L, Scharf M, Dehais C, Leclercq D, et al. . Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurol Neuroimmunol NeuroInflammation. (2017) 4:e326. 10.1212/NXI.0000000000000326</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000326</ArticleId>
            <ArticleId IdType="pmc">PMC5292928</ArticleId>
            <ArticleId IdType="pubmed">28203616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Sabater L, Saiz A, Serra C, Claramonte B, Graus F. Carbonic anhydrase-related protein VlII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol. (2004) 56:575–9. 10.1002/ana.20238</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20238</ArticleId>
            <ArticleId IdType="pubmed">15389893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Sabater L, Velasco F, Ciordia R, Dalmau J, Graus F. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol. (2014) 40:650–3. 10.1111/nan.12118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12118</ArticleId>
            <ArticleId IdType="pmc">PMC4077932</ArticleId>
            <ArticleId IdType="pubmed">24446689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaff E, Maat P, Hulsenboom E, van Den Berg R, van Den Bent M, Demmers J, et al. . Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol. (2012) 71:815–24. 10.1002/ana.23550</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23550</ArticleId>
            <ArticleId IdType="pubmed">22447725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Probst C, Komorowski L, de Graaff E, van Coevorden-Hameete M, Rogemond V, Honnorat J, et al. . Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e68. 10.1212/NXI.0000000000000068</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000068</ArticleId>
            <ArticleId IdType="pmc">PMC4345632</ArticleId>
            <ArticleId IdType="pubmed">25745634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J, Valldeoriola F, Ferrer I, Reñé R, Marin C, et al. . Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol. (1997) 74:55–61. 10.1016/S0165-5728(96)00205-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(96)00205-6</ArticleId>
            <ArticleId IdType="pubmed">9119979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trotter JL, Hendin BA, Osterland K. Cerebellar degeneration with Hodgkin's disease. Arch Neurol. (1976) 33:660–1. 10.1001/archneur.1976.00500090066014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1976.00500090066014</ArticleId>
            <ArticleId IdType="pubmed">962649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. . Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology. (2003) 60:230–4. 10.1212/01.WNL.0000041495.87539.98</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000041495.87539.98</ArticleId>
            <ArticleId IdType="pubmed">12552036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, Will LM, Hulsenboom E, Demonet JF, et al. . Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Ann Clin Transl Neurol. (2017) 4:680–6. 10.1002/acn3.396</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.396</ArticleId>
            <ArticleId IdType="pmc">PMC5590547</ArticleId>
            <ArticleId IdType="pubmed">28904989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do LD, Gupton SL, Tanji K, Bastien J, Brugière S, Couté Y, et al. . TRIM9 and TRIM67 are new targets in paraneoplastic cerebellar degeneration. Cerebellum. (2019) 18:245–54. 10.1007/s12311-018-0987-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12311-018-0987-5</ArticleId>
            <ArticleId IdType="pmc">PMC6445697</ArticleId>
            <ArticleId IdType="pubmed">30350014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MAM, et al. . Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol. (2011) 29:535–41. 10.1038/nbt.1856</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1856</ArticleId>
            <ArticleId IdType="pmc">PMC4169279</ArticleId>
            <ArticleId IdType="pubmed">21602805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu F, Takeshita Y, Sano Y, Hamamoto Y, Shiraishi H, Sato T, et al. . GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain. (2019) 142:2253–64. 10.1093/brain/awz168</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz168</ArticleId>
            <ArticleId IdType="pubmed">31236596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hulsenboom E, Sabater L, Hoogenraad CC, et al. . Plasticity-related gene 5: a novel surface autoantigen in paraneoplastic cerebellar degeneration. Neurol Neuroimmunol NeuroInflamm. (2015) 2:e156. 10.1212/NXI.0000000000000156</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000156</ArticleId>
            <ArticleId IdType="pmc">PMC4582903</ArticleId>
            <ArticleId IdType="pubmed">26445730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, et al. . Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. (2019) 6:e612. 10.1212/NXI.0000000000000612</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
            <ArticleId IdType="pmc">PMC6745726</ArticleId>
            <ArticleId IdType="pubmed">31511329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miske R, Gross CC, Scharf M, Golombeck KS, Hartwig M, Bhatia U, et al. . Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurol Neuroimmunol NeuroInflamm. (2017) 4:e307. 10.1212/NXI.0000000000000307</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000307</ArticleId>
            <ArticleId IdType="pmc">PMC5141526</ArticleId>
            <ArticleId IdType="pubmed">27957508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat JA, Sebastian Lopez-Chiriboga A, Kryzer TJ, Fryer JP, Devine M, Flores A, et al. . Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol NeuroInflamm. (2018) 5:e474. 10.1212/NXI.0000000000000474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000474</ArticleId>
            <ArticleId IdType="pmc">PMC6039209</ArticleId>
            <ArticleId IdType="pubmed">29998156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A, Gigli GL, Segatti S, Corazza E, Marini A, Bernardini A, et al. . Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. (2020) 267:26–35. 10.1007/s00415-019-09544-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-019-09544-1</ArticleId>
            <ArticleId IdType="pubmed">31552550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia Cuartero I, Rodriguez Galdeano M, Perez Pinar M, Solis Garcia del Pozo J. Thymic carcinoma associated with cerebellar degeneration. Eur J Case Rep Intern Med. (2018) 5:000780. 10.12890/2018_000780</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12890/2018_000780</ArticleId>
            <ArticleId IdType="pmc">PMC6346953</ArticleId>
            <ArticleId IdType="pubmed">30756016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ducray F, Demarquay G, Graus F, Decullier E, Antoine JC, Giometto B, et al. . Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. Eur J Neurol. (2014) 21:731–5. 10.1111/ene.12368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12368</ArticleId>
            <ArticleId IdType="pubmed">24471811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joubert B, Rostásy K, Honnorat J. Immune-mediated ataxias. Handb Clin Neurol. (2018) 155:313–32. 10.1016/B978-0-444-64189-2.00021-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-444-64189-2.00021-4</ArticleId>
            <ArticleId IdType="pubmed">29891069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, et al. . Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. (2003) 126:1409–18. 10.1093/brain/awg133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Wildemann B. “Medusa-head ataxia”: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 anti-CARP VIII. J Neuroinflammation. (2015) 12:166. 10.1186/s12974-015-0356-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0356-y</ArticleId>
            <ArticleId IdType="pmc">PMC4574226</ArticleId>
            <ArticleId IdType="pubmed">26377085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A, Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies – a review. Ann Clin Transl Neurol. (2016) 3:655–63. 10.1002/acn3.328</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.328</ArticleId>
            <ArticleId IdType="pmc">PMC4999597</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, et al. . Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol. (1997) 244:85–9. 10.1007/s004150050054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004150050054</ArticleId>
            <ArticleId IdType="pubmed">9120501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rana AQ, Rana AN, Adlul A. Acute ataxia due to anti-Yo antibody paraneoplastic cerebellar degeneration 4 months prior to diagnosis of uterine carcinoma. Acta Neurol Belg. (2012) 112:303–4. 10.1007/s13760-012-0047-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13760-012-0047-8</ArticleId>
            <ArticleId IdType="pubmed">22426676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasadsri L, Lee J, Wang BH, Yekkirala L, Wang M. Anti-Yo associated paraneoplastic cerebellar degeneration in a man with large cell cancer of the lung. Case Rep Neurol Med. (2013) 2013:725936. 10.1155/2013/725936</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/725936</ArticleId>
            <ArticleId IdType="pmc">PMC3792504</ArticleId>
            <ArticleId IdType="pubmed">24167748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruhnding A, Notch D, Beard A. Anti-Yo positive paraneoplastic cerebellar degeneration in the setting of cholangiocarcinoma. J Clin Neurosci. (2017) 36:71–2. 10.1016/j.jocn.2016.10.034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2016.10.034</ArticleId>
            <ArticleId IdType="pubmed">27816258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci. (1997) 17:1406–15. 10.1523/JNEUROSCI.17-04-01406.1997</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.17-04-01406.1997</ArticleId>
            <ArticleId IdType="pmc">PMC6793730</ArticleId>
            <ArticleId IdType="pubmed">9006982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE. Anti-Yo autoimmunity; dangerous for the brain but not the tumor?
J Neurol Sci. (2006) 250:1–2. 10.1016/j.jns.2006.08.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2006.08.001</ArticleId>
            <ArticleId IdType="pubmed">17010383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Totland C, Aarskog NK, Eichler TW, Haugen M, Nøstbakken JK, Monstad SE, et al. . CDR2 antigen and Yo antibodies. Cancer Immunol Immunother. (2011) 60:283–9. 10.1007/s00262-010-0943-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-010-0943-9</ArticleId>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen HB, Storstein A, et al. . Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunol Immunother. (2017) 66:1463–71. 10.1007/s00262-017-2041-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-2041-8</ArticleId>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okano HJ, Park W, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function : implications for neuronal and tumor cell survival. Genes Dev. (1999) 13:2087–97. 10.1101/gad.13.16.2087</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.13.16.2087</ArticleId>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Donovan KJ, Diedler J, Couture GC, Fak JJ, Darnell RB. The onconeural antigen cdr2 is a novel APC / C target that acts in mitosis to regulate C-Myc target genes in mammalian tumor cells. PLoS One. (2010) 5:e10045. 10.1371/journal.pone.0010045</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0010045</ArticleId>
            <ArticleId IdType="pmc">PMC2850929</ArticleId>
            <ArticleId IdType="pubmed">20383333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y. PKN interacts with a paraneoplastic cerebellar degeneration-associated antigen, which is a potential transcription factor. Exp Cell Res. (1998) 241:363–72. 10.1006/excr.1998.4060</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/excr.1998.4060</ArticleId>
            <ArticleId IdType="pubmed">9637778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K, Shirakawa T, Li Y, Kitagawa Y, Hirose G. Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X. Mol Cell Neurosci. (2002) 19:477–84. 10.1006/mcne.2001.1059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/mcne.2001.1059</ArticleId>
            <ArticleId IdType="pubmed">11988016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G. Effect of a paraneoplastic cerebellar degeneration-associated neural protein on B-myb promoter activity. Neurobiol Dis. (2004) 15:529–33. 10.1016/j.nbd.2003.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nbd.2003.11.003</ArticleId>
            <ArticleId IdType="pubmed">15056460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai K, Kitagawa Y, Li Y, Shirakawa T, Hirose G. Suppression of the transcriptional activity and DNA binding of nuclear factor-kappa B by a paraneoplastic cerebellar degeneration-associated antigen. J Neuroimmunol. (2001) 119:10–5. 10.1016/S0165-5728(01)00368-X</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(01)00368-X</ArticleId>
            <ArticleId IdType="pubmed">11525795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kråkenes T, Herdlevær I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L is the major Yo antibody target in paraneoplastic cerebellar degeneration. Ann Neurol. (2019) 86:316–21. 10.1002/ana.25511</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25511</ArticleId>
            <ArticleId IdType="pubmed">31148214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, et al. . A T cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci USA. (2007) 104:19073–8. 10.1073/pnas.0704336104</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0704336104</ArticleId>
            <ArticleId IdType="pmc">PMC2141910</ArticleId>
            <ArticleId IdType="pubmed">18045792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blachère NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M, et al. . T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol. (2014) 44:3240–51. 10.1002/eji.201444624</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201444624</ArticleId>
            <ArticleId IdType="pmc">PMC4296561</ArticleId>
            <ArticleId IdType="pubmed">25103845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see and don't see. Nat Rev Immunol. (2014) 14:377–91. 10.1038/nri3667</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3667</ArticleId>
            <ArticleId IdType="pmc">PMC4757912</ArticleId>
            <ArticleId IdType="pubmed">24830344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondo K, Ohigashi I, Takahama Y. Thymus machinery for T-cell selection. Int Immunol. (2019) 31:119–25. 10.1093/intimm/dxy081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxy081</ArticleId>
            <ArticleId IdType="pmc">PMC6400048</ArticleId>
            <ArticleId IdType="pubmed">30476234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. . Projection of an immunological self-shadow within the thymus by the aire protein. Science. (2002) 298:1395–401. 10.1126/science.1075958</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1075958</ArticleId>
            <ArticleId IdType="pubmed">12376594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malchow S, Leventhal DS, Lee V, Nishi S, Socci ND, Savage PA. Aire enforces immune tolerance by directing autoreactive T cells into the regulatory T cell lineage. Immunity. (2016) 44:1102–13. 10.1016/j.immuni.2016.02.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.02.009</ArticleId>
            <ArticleId IdType="pmc">PMC4871732</ArticleId>
            <ArticleId IdType="pubmed">27130899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Immunological Genome Project. Available online at: http://www.immgen.org/databrowser/index.html?gene_symbol=CDR2 [accessed April 1, 2020].</Citation>
        </Reference>
        <Reference>
          <Citation>Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, et al. . Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. Br J Cancer. (2018) 119:105–13. 10.1038/s41416-018-0125-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-018-0125-7</ArticleId>
            <ArticleId IdType="pmc">PMC6035206</ArticleId>
            <ArticleId IdType="pubmed">29899393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu W, Jiang N, Ebert PJR, Kidd BA, Müller S, Peder J, et al. . Clonal deletion prunes, but does not eliminate self-specific αβ CD8+T lymphocytes. Immunity. (2015) 42:929–41. 10.1016/j.immuni.2015.05.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2015.05.001</ArticleId>
            <ArticleId IdType="pmc">PMC4455602</ArticleId>
            <ArticleId IdType="pubmed">25992863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carl PL, Temple BRS, Cohen PL. Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity. Arthritis Res Ther. (2005) 7:R1360–74. 10.1186/ar1832</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/ar1832</ArticleId>
            <ArticleId IdType="pmc">PMC1297582</ArticleId>
            <ArticleId IdType="pubmed">16277689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell JC, Albert ML, Darnell RB. cdr2, a target antigen of naturally occurring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res. (2000) 60:2136–9. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10786675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blachère NE, Orange DE, Gantman EC, Santomasso BD, Couture GC, Ramirez-Montagut T, et al. 
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy. JCI Insight. (2017) 2:e96173
10.1172/jci.insight.96173</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.96173</ArticleId>
            <ArticleId IdType="pmc">PMC5752293</ArticleId>
            <ArticleId IdType="pubmed">29093272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, et al. . Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. (2018) 135:569–79. 10.1007/s00401-017-1802-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-017-1802-y</ArticleId>
            <ArticleId IdType="pubmed">29299667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, et al. . Selective accumulation of mature DC-lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. (2004) 64:2192–8. 10.1158/0008-5472.CAN-03-2969</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-03-2969</ArticleId>
            <ArticleId IdType="pubmed">15026362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. (2012) 33:579–89. 10.1016/j.it.2012.07.004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2012.07.004</ArticleId>
            <ArticleId IdType="pubmed">22926201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerfoot SM, Kubes P. Overlapping roles of P-selectin and α 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol. (2002) 169:1000–6. 10.4049/jimmunol.169.2.1000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.169.2.1000</ArticleId>
            <ArticleId IdType="pubmed">12097407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vajkoczy P, Laschinger M, Engelhardt B. α4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest. (2001) 108:557–65. 10.1172/JCI12440</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI12440</ArticleId>
            <ArticleId IdType="pmc">PMC209399</ArticleId>
            <ArticleId IdType="pubmed">11518729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauer M, Brakebusch C, Coisne C, Sixt M, Wekerle H, Engelhardt B, et al. . β1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc Natl Acad Sci USA. (2009) 106:1920–5. 10.1073/pnas.0808909106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0808909106</ArticleId>
            <ArticleId IdType="pmc">PMC2644139</ArticleId>
            <ArticleId IdType="pubmed">19179279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman DW, Klein RS, Ransohoff RM. The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta Mol Basis Dis. (2011) 1812:220–30. 10.1016/j.bbadis.2010.07.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2010.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC3005102</ArticleId>
            <ArticleId IdType="pubmed">20692338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. (2012) 12:623–35. 10.1038/nri3265</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3265</ArticleId>
            <ArticleId IdType="pubmed">22903150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, et al. . CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood. (2003) 101:4775–82. 10.1182/blood-2002-10-3309</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2002-10-3309</ArticleId>
            <ArticleId IdType="pubmed">12595306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ifergan I, Kebir H, Alvarez JI, Marceau G, Bernard M, Bourbonnire L, et al. . Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain. (2011) 134:3557–74. 10.1093/brain/awr268</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awr268</ArticleId>
            <ArticleId IdType="pmc">PMC7110084</ArticleId>
            <ArticleId IdType="pubmed">22058139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Blondel G, Pignolet B, Tietz S, Yshii L, Gebauer C, Perinat T, et al. . Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the α4β1-integrin. Eur J Immunol. (2015) 45:3302–12. 10.1002/eji.201545632</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201545632</ArticleId>
            <ArticleId IdType="pmc">PMC7163664</ArticleId>
            <ArticleId IdType="pubmed">26358409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hottinger AF, de Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R. Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol NeuroInflamm. (2018) 5:e439. 10.1212/NXI.0000000000000439</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000439</ArticleId>
            <ArticleId IdType="pmc">PMC6225924</ArticleId>
            <ArticleId IdType="pubmed">30465016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross CC, Meyer C, Bhatia U, Yshii L, Kleffner I, Bauer J, et al. . CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nat Commun. (2019) 10:5779. 10.1038/s41467-019-13593-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-13593-5</ArticleId>
            <ArticleId IdType="pmc">PMC6920411</ArticleId>
            <ArticleId IdType="pubmed">31852955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilhelm I, Nyúl-Tóth Á, Suciu M, Hermenean A, Krizbai IA. Heterogeneity of the blood-brain barrier. Tissue Barriers. (2016) 4:e1143544. 10.1080/21688370.2016.1143544</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21688370.2016.1143544</ArticleId>
            <ArticleId IdType="pmc">PMC4836475</ArticleId>
            <ArticleId IdType="pubmed">27141424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. (1995) 96:1698–705. 10.1172/JCI118214</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI118214</ArticleId>
            <ArticleId IdType="pmc">PMC185805</ArticleId>
            <ArticleId IdType="pubmed">7560060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yasuda K, Cline C, Lin YS, Scheib R, Ganguly S, Thirumaran RK, et al. . In vivo imaging of human MDR1 transcription in the brain and spine of MDR1-luciferase reporter mice. Drug Metab Dispos. (2015) 43:1646–54. 10.1124/dmd.115.065078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/dmd.115.065078</ArticleId>
            <ArticleId IdType="pmc">PMC4613952</ArticleId>
            <ArticleId IdType="pubmed">26281846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, et al. . Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol. (1996) 91:519–25. 10.1007/s004010050460</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004010050460</ArticleId>
            <ArticleId IdType="pubmed">8740233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE, Brashear RH. Antibodies to cerebellar Purkmje cells in patients with paraneoplastic cerebellar degeneration and ovarian Carcinoma. Ann Neurol. (1983) 14:609–13. 10.1002/ana.410140603</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410140603</ArticleId>
            <ArticleId IdType="pubmed">6360029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, et al. . Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol. (1997) 23:468–74. 10.1046/j.1365-2990.1997.00078.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2990.1997.00078.x</ArticleId>
            <ArticleId IdType="pubmed">9460712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with yo antibodies. Acta Neurol Scand. (2009) 120:64–7. 10.1111/j.1600-0404.2008.01138.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2008.01138.x</ArticleId>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aye MM, Kasai T, Tashiro Y, Xing HQ, Shirahama H, Mitsuda M, et al. . CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J Neuroimmunol. (2009) 208:136–40. 10.1016/j.jneuroim.2009.01.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.01.017</ArticleId>
            <ArticleId IdType="pubmed">19217169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aboul-Enein F, Höftberger R, Buxhofer-Ausch V, Drlicek M, Lassmann H, Budka H, et al. . Neocortical neurones may be targeted by immune attack in anti-Yo paraneoplastic syndrome. Neuropathol Appl Neurobiol. (2008) 34:248–52. 10.1111/j.1365-2990.2007.00909.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.2007.00909.x</ArticleId>
            <ArticleId IdType="pubmed">17995920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, et al. . Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. (2012) 135:1622–38. 10.1093/brain/aws082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws082</ArticleId>
            <ArticleId IdType="pubmed">22539258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McConnell MJ, Huang YH, Datwani A, Shatz CJ. H2-K b and H2-D b regulate cerebellar long-term depression and limit motor learning. Proc Natl Acad Sci USA. (2009) 106:6784–9. 10.1073/pnas.0902018106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0902018106</ArticleId>
            <ArticleId IdType="pmc">PMC2672503</ArticleId>
            <ArticleId IdType="pubmed">19346486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii L, Pignolet B, Mauré E, Pierau M, Brunner-Weinzierl M, Hartley O, et al. . IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration. JCI Insight. (2019) 4:127001. 10.1172/jci.insight.127001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.127001</ArticleId>
            <ArticleId IdType="pmc">PMC6483638</ArticleId>
            <ArticleId IdType="pubmed">30944244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pellkofer H, Schubart AS, Höftberger R, Schutze N, Pagany M, Schüller M, et al. . Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain. (2004) 127:1822–30. 10.1093/brain/awh205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh205</ArticleId>
            <ArticleId IdType="pubmed">15201193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gebauer C, Pignolet B, Yshii L, Mauré E, Bauer J, Liblau R. CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. Oncoimmunology. (2017) 6:e1260212. 10.1080/2162402X.2016.1260212</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2016.1260212</ArticleId>
            <ArticleId IdType="pmc">PMC5353919</ArticleId>
            <ArticleId IdType="pubmed">28344867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii LM, Gebauer CM, Pignolet B, Mauré E, Quériault C, Pierau M, et al. . CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. (2016) 139:2923–34. 10.1093/brain/aww225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww225</ArticleId>
            <ArticleId IdType="pubmed">27604307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE, Parks T, Jaeckle K. Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology. (1993) 43:2049–54. 10.1212/WNL.43.10.2049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.43.10.2049</ArticleId>
            <ArticleId IdType="pubmed">8413965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA. (1996) 93:4529–36. 10.1073/pnas.93.10.4529</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.10.4529</ArticleId>
            <ArticleId IdType="pmc">PMC39311</ArticleId>
            <ArticleId IdType="pubmed">8643438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combi. Clin Neurol Neurosurg. (1995) 97:101–5. 10.1016/0303-8467(95)00005-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0303-8467(95)00005-5</ArticleId>
            <ArticleId IdType="pubmed">7788964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smitt S, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen hud does not cause neurologic disease in mice. Neurology. (1995) 45:1873–8. 10.1212/WNL.45.10.1873</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.45.10.1873</ArticleId>
            <ArticleId IdType="pubmed">7477985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res. (1998) 4:2819–24. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9829748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panja D, Vedeler CA, Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol Appl Neurobiol. (2019) 45:141–56. 10.1111/nan.12492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12492</ArticleId>
            <ArticleId IdType="pmc">PMC7379599</ArticleId>
            <ArticleId IdType="pubmed">29679372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE, Clawson SA, Hill KE, Wood B, Clardy SL, Tsunoda I, et al. . Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. PLoS One. (2015) 10:e0123446. 10.1371/journal.pone.0123446</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0123446</ArticleId>
            <ArticleId IdType="pmc">PMC4401511</ArticleId>
            <ArticleId IdType="pubmed">25885452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, de Ponti F, et al. . Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology. (2003) 125:70–9. 10.1016/S0016-5085(03)00664-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0016-5085(03)00664-4</ArticleId>
            <ArticleId IdType="pubmed">12851872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. (2010) 69:997–1007. 10.1097/NEN.0b013e3181f0c82b</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e3181f0c82b</ArticleId>
            <ArticleId IdType="pmc">PMC2959164</ArticleId>
            <ArticleId IdType="pubmed">20838245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. (2017) 13:755–63. 10.1038/nrneurol.2017.144</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2017.144</ArticleId>
            <ArticleId IdType="pubmed">29104289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, et al. . Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol NeuroInflamm. (2019) 6:e604. 10.1212/NXI.0000000000000604</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000604</ArticleId>
            <ArticleId IdType="pmc">PMC6705619</ArticleId>
            <ArticleId IdType="pubmed">31454760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams TJ, Benavides DR, Patrice K-A, Dalmau JO, de Ávila ALR, Le DT, et al. . Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. (2016) 73:928. 10.1001/jamaneurol.2016.1399</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2016.1399</ArticleId>
            <ArticleId IdType="pubmed">27271951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, et al. . Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. (2017) 22:709–18. 10.1634/theoncologist.2016-0487</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2016-0487</ArticleId>
            <ArticleId IdType="pmc">PMC5469590</ArticleId>
            <ArticleId IdType="pubmed">28495807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. . Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. (2017) 170:1120–33. 10.1016/j.cell.2017.07.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.07.024</ArticleId>
            <ArticleId IdType="pmc">PMC5591072</ArticleId>
            <ArticleId IdType="pubmed">28803728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. (2019) 19:307–25. 10.1038/s41568-019-0144-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0144-6</ArticleId>
            <ArticleId IdType="pubmed">31092904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. (2020) 577:549–55. 10.1038/s41586-019-1922-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1922-8</ArticleId>
            <ArticleId IdType="pubmed">31942075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph CG, Darrah E, Shah AA, Skora AD, Livia A, Wigley FM, et al. . Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. (2014) 343:152–7. 10.1126/science.1246886</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1246886</ArticleId>
            <ArticleId IdType="pmc">PMC4038033</ArticleId>
            <ArticleId IdType="pubmed">24310608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. (2000) 47:9–17. 10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200001)47:1&lt;9::AID-ANA5&gt;3.0.CO;2-I</ArticleId>
            <ArticleId IdType="pubmed">10632096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beltrán E, Gerdes LA, Hansen J, Flierl-Hecht A, Krebs S, Blum H, et al. . Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. J Clin Invest. (2019) 129:4758–68. 10.1172/JCI128475</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI128475</ArticleId>
            <ArticleId IdType="pmc">PMC6819125</ArticleId>
            <ArticleId IdType="pubmed">31566584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahrends T, Spanjaard A, Pilzecker B, Babała N, Bovens A, Xiao Y, et al. . CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. (2017) 47:848–61.e5. 10.1016/j.immuni.2017.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.10.009</ArticleId>
            <ArticleId IdType="pubmed">29126798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts WK, Blachère NE, Frank MO, Dousmanis A, Ransohoff RM, Darnell RB. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. Ann Neurol. (2015) 78:619–29. 10.1002/ana.24494</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24494</ArticleId>
            <ArticleId IdType="pmc">PMC4583819</ArticleId>
            <ArticleId IdType="pubmed">26224283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Liberto G, Pantelyushin S, Kreutzfeldt M, Page N, Musardo S, Coras R, et al. . Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping. Cell. (2018) 175:458–71.e19. 10.1016/j.cell.2018.07.049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.07.049</ArticleId>
            <ArticleId IdType="pubmed">30173917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann H, Cavalié A, Jenne D, Wekerle H. Major Histocompatibility Complex (MHC) Class I gene expression in singe neurons of the central nervous system : differential regulationby interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J Exp Med. (1997) 185:305–16. 10.1084/jem.185.2.305</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.185.2.305</ArticleId>
            <ArticleId IdType="pmc">PMC2196130</ArticleId>
            <ArticleId IdType="pubmed">9016879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tröscher AR, Wimmer I, Quemada-Garrido L, Köck U, Gessl D, Verberk SGS, et al. . Microglial nodules provide the environment for pathogenic T cells in human encephalitis. Acta Neuropathol. (2019) 137:619–35. 10.1007/s00401-019-01958-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-019-01958-5</ArticleId>
            <ArticleId IdType="pmc">PMC6426829</ArticleId>
            <ArticleId IdType="pubmed">30663001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galli J, Greenlee J. Paraneoplastic diseases of the central nervous system. Lancet Neurol. (2020) 9:167. 10.12688/f1000research.21309.1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12688/f1000research.21309.1</ArticleId>
            <ArticleId IdType="pmc">PMC7062203</ArticleId>
            <ArticleId IdType="pubmed">32194943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flach AC, Litke T, Strauss J, Haberl M, Cordero Gómez C, Reindl M, et al. . Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc Natl Acad Sci USA. (2016) 113:3323–8. 10.1073/pnas.1519608113</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1519608113</ArticleId>
            <ArticleId IdType="pmc">PMC4812745</ArticleId>
            <ArticleId IdType="pubmed">26957602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meloni C, Iani C, Dominijanni S, Arciprete F, Cipriani S, Caramiello MS, et al. . A case report of plasma exchange therapy in non-paraneoplastic cerebellar ataxia associated with Anti-Yo antibody. Ther Apher Dial. (2004) 8:500–2. 10.1111/j.1774-9987.2004.00198.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1774-9987.2004.00198.x</ArticleId>
            <ArticleId IdType="pubmed">15663551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thöne J, Hohaus A, Lamprecht S, Bickel A, Erbguth F. Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci. (2008) 272:171–3. 10.1016/j.jns.2008.04.020</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2008.04.020</ArticleId>
            <ArticleId IdType="pubmed">18632117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van Den Bent M, van't Veer M, et al. . An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. (2006) 253:16–20. 10.1007/s00415-005-0882-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-005-0882-0</ArticleId>
            <ArticleId IdType="pubmed">16444604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al. . Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. (2000) 55:713–5. 10.1212/WNL.55.5.713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schessl J, Schuberth M, Reilich P, Schneiderat P, Strigl-Pill N, Walter MC, et al. . Long-term efficiency of intravenously administered immunoglobulin in anti-yo syndrome with paraneoplastic cerebellar degeneration. J Neurol. (2011) 258:946–7. 10.1007/s00415-010-5859-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-010-5859-y</ArticleId>
            <ArticleId IdType="pubmed">21174114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-purkinje cell antibody. J Neurooncol. (2007) 81:67–9. 10.1007/s11060-006-9198-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-006-9198-x</ArticleId>
            <ArticleId IdType="pubmed">16773214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker SK, Morillo C, Vernino S. Autoimmune autonomic ganglionopathy with late-onset encephalopathy. Auton Neurosci Basic Clin. (2009) 146:29–32. 10.1016/j.autneu.2008.10.016</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autneu.2008.10.016</ArticleId>
            <ArticleId IdType="pubmed">19028442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daver N, McClain K, Allen CE, Parikh SA, Otrock Z, Rojas-Hernandez C, et al. . A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. (2017) 123:3229–40. 10.1002/cncr.30826</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.30826</ArticleId>
            <ArticleId IdType="pmc">PMC5568927</ArticleId>
            <ArticleId IdType="pubmed">28621800</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
